Akamis Bio, Parker Institute for Cancer Immunotherapy and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer
“Pancreatic cancer is one of the most complex and difficult to treat cancers. The wide variety of cell types, molecular pathways, and immune resistance mechanisms involved in the development and progression of the disease make it nearly impossible to treat with a single agent,” said Robert Vonderheide, M.D., D.Phil., Director of the Abramson Cancer Center at Penn Medicine and lead investigator of the REVOLUTION study. “REVOLUTION was specifically designed to identify combination therapies with the potential to have a meaningful impact on disease progression. We look forward to further exploring the CD40 agonist mechanism of action for people with pancreatic cancer who are in dire need of additional treatment options.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.